Abstract：
Most hematopoietic stem cell transplants performed for an autoimmune disease of the nervous system, use the patient\'s hematopoietic stem cells (HSCs). Obtaining an HSC graft is the first step of the process. This typically involves mobilization of bone marrow HSCs into the circulation using high-dose cyclophosphamide followed by filgrastim, a drug based on granulocyte colony-stimulating factor. Toxicity from these agents is usually manageable and adverse events are less severe and less frequent than those experienced during the hematopoietic stem cell transplant. Following mobilization, HSCs are collected from the circulation by leukapheresis. Some centers deplete the graft of lymphocytes using an ex vivo immunomagnetic selection procedure. HSC grafts are cryopreserved until required for the stem cell transplant. Quality testing of the graft ensures sterility and it contains sufficient HSCs and hematopoietic progenitors. The clinical and laboratory aspects of HSC graft mobilization, collection, and storage must meet standards set by national regulatory bodies and accredited by international professional standards organizations. Experienced stem cell transplant teams are important for minimizing procedural toxicity and enhancing successful collection.
摘要：
大多数造血干细胞移植用于神经系统自身免疫性疾病，使用患者的造血干细胞（HSC）。获得HSC接枝是该方法的第一步。这通常涉及使用高剂量环磷酰胺和非格司亭将骨髓HSC动员到循环中，一种基于粒细胞集落刺激因子的药物。与造血干细胞移植期间经历的那些相比,这些药物的毒性通常是可控的,并且不良事件较不严重和较不频繁。动员后,通过白细胞去除术从循环中收集HSC。一些中心使用离体免疫磁性选择程序耗尽淋巴细胞的移植物。将HSC移植物冷冻保存直到干细胞移植需要。移植物的质量测试确保了无菌性,并且其含有足够的HSC和造血祖细胞。HSC移植物动员的临床和实验室方面，收藏,和存储必须符合国家监管机构制定的标准，并得到国际专业标准组织的认可。经验丰富的干细胞移植团队对于最大程度地减少程序毒性和增强成功收集非常重要。
